Gene Editing Therapies Targeting Lipid Metabolism for Cardiovascular Disease: Tools, Delivery Strategies, and Clinical Progress
Cells · 12.01.2026 · 15 (2) · 134
DOI: 10.3390/cells15020134 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 12.01.2026. Verfasst von Zhuoying Ren und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical School, 2800 Plymouth Road, Ann Arbor, MI 4810…. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Lipid Metabolism, Gene Editing, Genetic Therapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 232 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, National Institutes of Health grants.
Abstract (Originalsprache)
Gene editing technologies have revolutionized therapeutic development, offering potentially curative and preventative strategies for cardiovascular disease (CVD), which remains a leading global cause of morbidity and mortality. This review provides an introduction to the state-of-the-art gene editing tools—including ZFNs, TALENs, CRISPR/Cas9 systems, base editors, and prime editors—and evaluates their application in lipid metabolic pathways central to CVD pathogenesis. Emphasis is placed on targets such as PCSK9, ANGPTL3, CETP, APOC3, ASGR1, LPA, and IDOL, supported by findings from human genetics, preclinical models, and recent first-in-human trials. Emerging delivery vehicles (AAVs, LNPs, lentivirus, virus-like particles) and their translational implications are discussed. The review highlights ongoing clinical trials employing liver-targeted in vivo editing modalities (LivGETx-CVD) and provides insights into challenges in delivery, off-target effects, genotoxicity, and immunogenicity. Collectively, this review captures the rapid progress of LivGETx-CVD from conceptual innovation to clinical application, and positions gene editing as a transformative, single-dose strategy with the potential to redefine prevention and long-term management of dyslipidemia and atherosclerotic cardiovascular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Advanced Models for Translational Sciences and Therapeutics, University of Michigan Medical School, 2800 Plymouth Road, Ann Arbor, MI 48109, USA.
ORCID-Profile: Zhuoying Ren, Jun Zhou, Jie Xu
Förderung
- NIGMS NIH HHS
- National Institutes of Health grants
Zitieren
APA
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026). Gene Editing Therapies Targeting Lipid Metabolism for Cardiovascular Disease: Tools, Delivery Strategies, and Clinical Progress. Cells, 15(2), 134. https://doi.org/10.3390/cells15020134
Vancouver
Ren Z, Zhou J, Yang D, Guo Y, Zhang J, Xu J, et al. Gene Editing Therapies Targeting Lipid Metabolism for Cardiovascular Disease: Tools, Delivery Strategies, and Clinical Progress. Cells. 2026;15(2):134. doi:10.3390/cells15020134
BibTeX
@article{Ren2026,
author = {Ren, Zhuoying and Zhou, Jun and Yang, Dongshan and Guo, Yanhong and Zhang, Jifeng and Xu, Jie and Chen, Y Eugene},
title = {Gene Editing Therapies Targeting Lipid Metabolism for Cardiovascular Disease: Tools, Delivery Strategies, and Clinical Progress},
journal = {Cells},
year = {2026},
volume = {15},
number = {2},
pages = {134},
doi = {10.3390/cells15020134}
}
EUVIMED